Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Abstracts of Papers Presented at the 1997 Meeting of the American Academy of Clinical Psychiatrists

Abstracts of Papers Presented at the 1997 Meeting of the American Academy of Clinical Psychiatrists Annals of Clinical Psychiatry, Vol. 10, No. 3, 1998 Abstracts of Papers Presented at the 1997 Meeting of the American Academy of Clinical Psychiatrists Guy E. Brannon, M.D., and Anita S. Kablinger, M.D. When the Depression Won't Go Away? tion-based organizational scheme accounts for all marketed antidepressants and conceptualizes these During an era of new and improved pharma- agents as falling into three principal classes defined cotherapy it would be expected that people suffering by the biological mechanism presumed to mediate from major depressive disorder (MDD) would re- antidepressant efficacy. The three classes include in- spond and improve with treatment. However, there hibitors of neuronal uptake of neurotransmitter, bio- are times when multiple and various treatment regi- genie amine receptor antagonists, and inhibitors of mens are ineffective. This leads one to reconsider the enzymatic metabolism of neurotransmitter. Within diagnosis or other alternatives including thoughts of each class, agents are further subdivided based on Axis II comorbidity. People with personality disor- the degree of selectivity for the antidepressant ders may have an earlier onset of MDD, which can mechanism over other nonantidepressant biological influence the course and outcome of the illness. A activities and the presence of more than one http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Abstracts of Papers Presented at the 1997 Meeting of the American Academy of Clinical Psychiatrists

Annals of Clinical Psychiatry , Volume 10 (3) – Oct 13, 2004

Loading next page...
 
/lp/springer-journals/abstracts-of-papers-presented-at-the-1997-meeting-of-the-american-qeuYHKyA4y
Publisher
Springer Journals
Copyright
Copyright © 1998 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1022358523009
Publisher site
See Article on Publisher Site

Abstract

Annals of Clinical Psychiatry, Vol. 10, No. 3, 1998 Abstracts of Papers Presented at the 1997 Meeting of the American Academy of Clinical Psychiatrists Guy E. Brannon, M.D., and Anita S. Kablinger, M.D. When the Depression Won't Go Away? tion-based organizational scheme accounts for all marketed antidepressants and conceptualizes these During an era of new and improved pharma- agents as falling into three principal classes defined cotherapy it would be expected that people suffering by the biological mechanism presumed to mediate from major depressive disorder (MDD) would re- antidepressant efficacy. The three classes include in- spond and improve with treatment. However, there hibitors of neuronal uptake of neurotransmitter, bio- are times when multiple and various treatment regi- genie amine receptor antagonists, and inhibitors of mens are ineffective. This leads one to reconsider the enzymatic metabolism of neurotransmitter. Within diagnosis or other alternatives including thoughts of each class, agents are further subdivided based on Axis II comorbidity. People with personality disor- the degree of selectivity for the antidepressant ders may have an earlier onset of MDD, which can mechanism over other nonantidepressant biological influence the course and outcome of the illness. A activities and the presence of more than one

Journal

Annals of Clinical PsychiatrySpringer Journals

Published: Oct 13, 2004

There are no references for this article.